FOUNDATION FOR THE NATIONAL INSTITUTE OF HEALTH INC: Form 990, tax year 2021
View the entire original 990 at ProPublica ↗
- Organization
- FOUNDATION FOR THE NATIONAL INSTITUTE OF HEALTH INC (EIN 52-1986675)
- Tax period
- 2021-01-01 to 2021-12-31
- Filed
- 2022-10-24
- IRS object ID
- 202222979349301767
- Schema version
- 2021v4.2
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule G
- Schedule I
- Schedule J
- Schedule M
- Schedule O
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2022-10-24T14:05:38-05:00 | ReturnTs |
| Tax Period End | 2021-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 440160260 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | FORVIS LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 901 EAST CARY STREET SUITE 1000 | AddressLine1Txt |
| City | RICHMOND | CityNm |
| State Abbreviation | VA | StateAbbreviationCd |
| ZIP | 23219 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2021-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 521986675 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | FOUNDATION FOR THE NATIONAL INSTITUTES | BusinessNameLine1Txt |
| Business Name Line2 | OF HEALTH INC | BusinessNameLine2Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | FOUN | BusinessNameControlTxt |
| Phone | 3014025311 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 11400 ROCKVILLE PIKE 600 | AddressLine1Txt |
| City | NORTH BETHESDA | CityNm |
| State Abbreviation | MD | StateAbbreviationCd |
| ZIP | 20852 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | DONALD M HILL | PersonNm |
| Person Title | CHIEF FINANCIAL OFFICER | PersonTitleTxt |
| Phone | 3014025311 | PhoneNum |
| Signature | 2022-10-21 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Signing Officer SigningOfficerGrp
Person Full Name PersonFullName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person First | DONALD | PersonFirstNm |
| Person Last | HILL | PersonLastNm |
| Field | Value | IRS element (for citing) |
|---|---|---|
| SSN | 999009999 | SSN |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | LAKRISHA J WATSON | PreparerPersonNm |
| PTIN | P01677333 | PTIN |
| Phone | 8042827636 | PhoneNum |
| Preparation | 2022-10-21 | PreparationDt |
Additional Filer Information AdditionalFilerInformation
Trusted Customer TrustedCustomerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Trusted Customer | 3 | TrustedCustomerCd |
| Authentication Assurance Level | AAL1 | AuthenticationAssuranceLevelCd |
| Identity Assurance Level | IAL1 | IdentityAssuranceLevelCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2021 | TaxYr |
| Build TS | 2022-09-23 18:48:47Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | DONALD M HILL | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 11400 ROCKVILLE PIKE 600 | AddressLine1Txt |
| City | NORTH BETHESDA | CityNm |
| State Abbreviation | MD | StateAbbreviationCd |
| ZIP | 20852 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $119,637,840 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | HTTP://WWW.FNIH.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1996 | FormationYr |
| Legal Domicile State | MD | LegalDomicileStateCd |
| Activity Or Mission | THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH CREATES AND MANAGES ALLIANCES WITH PUBLIC ANDPRIVATE INSTITUTIONS IN SUPPORT OF THE MISSION OF THE NIH, THE WORLD'S PREMIER MEDICAL RESEARCH AGENCY. THE FOUNDATION, ALSO KNOWN AS THE FNIH, WORKS WITH ITS PARTNERS TO ACCELERATE BIOMEDICAL RESEARCH AND STRATEGIES AGAINST DISEASES AND HEALTH CONCERNS IN THE UNITED STATES AND ACROSS THE GLOBE. THE FNIH ORGANIZES AND ADMINISTERS RESEARCH PROJECTS; SUPPORTS EDUCATION AND TRAINING OF NEW RESEARCHERS; ORGANIZES EDUCATIONAL EVENTS AND SYMPOSIA; AND ADMINISTERS A SERIES OF FUNDS SUPPORTING A WIDE RANGE OF HEALTH ISSUES. ESTABLISHED BY CONGRESS IN 1990, THE FNIH IS A NOT-FOR-PROFIT 501(C)(3) CHARITABLE ORGANIZATION. | ActivityOrMissionDesc |
| Voting Members Governing Body | 24 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 24 | VotingMembersIndependentCnt |
| Total Employee | 86 | TotalEmployeeCnt |
| Total Volunteers | 24 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $98,343,956 | PYContributionsGrantsAmt |
| CY Contributions Grants | $105,993,785 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $0 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $50,000 | CYProgramServiceRevenueAmt |
| PY Investment Income | $1,793,315 | PYInvestmentIncomeAmt |
| CY Investment Income | $1,523,894 | CYInvestmentIncomeAmt |
| PY Other Revenue | $42,551 | PYOtherRevenueAmt |
| CY Other Revenue | $38,012 | CYOtherRevenueAmt |
| PY Total Revenue | $100,179,822 | PYTotalRevenueAmt |
| CY Total Revenue | $107,605,691 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $23,094,805 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $20,925,571 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $11,036,676 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $11,200,771 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $112,270 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $24,522,875 | PYOtherExpensesAmt |
| CY Other Expenses | $26,276,294 | CYOtherExpensesAmt |
| PY Total Expenses | $58,654,356 | PYTotalExpensesAmt |
| CY Total Expenses | $58,402,636 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $41,525,466 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $49,203,055 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $171,939,741 | TotalAssetsBOYAmt |
| Total Assets EOY | $221,939,759 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $10,735,525 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $10,990,437 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $161,204,216 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $210,949,322 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | SEE SCHEDULE O, STATEMENT OF ORGANIZATION'S PRIMARY EXEMPT PURPOSE STATEMENTTHE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH CREATES AND LEADS ALLIANCES AND PUBLIC-PRIVATE PARTNERSHIPS THAT ADVANCE BREAKTHROUGH BIOMEDICAL DISCOVERIES AND IMPROVE THE QUALITY OF PEOPLE'S LIVES. | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $50,592,188 | ExpenseAmt |
| Grant | $19,914,025 | GrantAmt |
| Revenue | $50,000 | RevenueAmt |
| Desc | SEE SCHEDULE O, PROGRAM ONE, RESEARCH PROGRAMSPROGRAM ONE - RESEARCH PROGRAMS -ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES (ACTIV)COMBATING THE PANDEMIC WHEN DESPERATELY ILL COVID-19 PATIENTS FIRST BEGAN KNOCKING AT THE DOORS OF U.S. HOSPITALS, HEALTHCARE WORKERS FRANTICALLY SOUGHT TO DEVELOP EFFECTIVE TREATMENTS FOR THE DISEASE. ACROSS THE WORLD, INDIVIDUAL SCIENTISTS AS WELL AS RESEARCH INSTITUTIONS LAUNCHED HUNDREDS OF STUDIES TO TEST VARIOUS POTENTIAL REMEDIES. UNFORTUNATELY, MANY OF THESE STUDIES WERE TOO SMALL OR INADEQUATELY DESIGNED TO YIELD CONCLUSIVE RESULTS. MEANWHILE, A NUMBER OF UNSUBSTANTIATED REPORTS OF "EFFECTIVE" TREATMENTS FLOODED THE MEDIA, WHICH DID LITTLE TO RELIEVE THE "INFODEMIC" OVERWHELMING THE HEALTHCARE WORKERS TRYING TO HELP THESE PATIENTS.A NATIONALLY COORDINATED, FOCUSED PLAN FOR ADDRESSING THE PANDEMIC WAS CLEARLY NEEDED AND DR. FRANCIS COLLINS CALLED ON THE FNIH TO CREATE A SOLUTION. THE RESULTING ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES (ACTIV) PARTNERSHIP WAS FORMED IN RECORD TIME IN APRIL 2020. OVER THE FOLLOWING 10 MONTHS, ACTIV REVIEWED MORE THAN 800 POTENTIAL COVID-19 TREATMENTS AND LAUNCHED 11 ROBUSTLY DESIGNED "MASTER PROTOCOL" CLINICAL TRIALS, EACH CAPABLE OF TESTING MULTIPLE DRUGS IN A RELEVANT PATIENT POPULATION AND FUNDED THROUGH NIH BY THE U.S. GOVERNMENT'S OPERATION WARP SPEED INITIATIVE. SINCE ITS INCEPTION IN APRIL 2020, THE ACTIV TRIAL NETWORKS HAVE TESTED OVER 30 THERAPIES FOR EFFECTIVENESS AGAINST COVID-19.OF THESE PROMISING LEADS, SEVERAL HAVE ALREADY REPORTED RESULTS, WITH A MAJORITY OF THE TRIALS DUE TO READ OUT BY THE FALL OF 2022. DURING 2021, DATA FROM THE ACTIV TRIALS CONTRIBUTED TO EMERGENCY USE AUTHORIZATIONS FOR THREE TREATMENTS, INCLUDING THE MONOCLONAL ANTIBODY THERAPIES FROM BRII BIOSCIENCES, ELI LILLY, AND ASTRAZENECA, AND LED TO AN IMPORTANT CHANGE IN CLINICAL PRACTICE FOR THE USE OF ANTICOAGULATION THERAPIES IN HOSPITALIZED COVID-19 PATIENTS. IMPORTANTLY, ACTIV'S PRIORITIZATION EFFORTS MEANT THAT VALUABLE RESOURCES MONEY, LABORATORY SPACE, HEALTHCARE WORKERS' TIME, AND PATIENTS' HOPES WERE FOCUSED ON THERAPIES LIKELY TO SUCCEED AS COVID-19 TREATMENTS.ACTIV, WHICH INCLUDES EIGHT U.S. GOVERNMENT AGENCIES, FOUR NONPROFIT ORGANIZATIONS, AND 20 INDUSTRY PARTNERS, STANDS OUT AS PERHAPS THE MOST REMARKABLE COLLABORATION TO ARISE FROM THE COVID-19 RESPONSE. ITS FORMATION RELIED ON THE FNIH'S PROVEN PARTNERSHIP MODEL ENGAGE PEOPLE AND ORGANIZATIONS WITH DIVERSE KNOWLEDGE, UNIQUE CAPABILITIES, AND DISTINCT VIEWPOINTS AND CREATE AN ENVIRONMENT BASED ON OBJECTIVE SCIENCE WHERE TRUST AND THE EXCHANGE OF NEW IDEAS CAN THRIVE WHILE ACHIEVING ITS GOALS WITH UNPRECEDENTED SCALE AND SPEED. IT'S A BLUEPRINT THAT THE FNIH WILL CONTINUE TO FOLLOW TO TACKLE A HOST OF DIFFICULT BIOMEDICAL CHALLENGES STEMMING FROM THE CURRENT PANDEMIC AND MANY FUTURE CHALLENGES TO HUMAN HEALTH. TRACEIN EARLY 2020, SCIENTISTS AT THE NIH AND AROUND THE WORLD QUICKLY HAD SEQUENCED THE NEW SARS-COV-2 VIRUS AND HAD BEGUN TO CREATE EFFECTIVE TOOLS FOR STOPPING IT. BUT THEN CAME THE BETA VARIANT. GAMMA, DELTA, AND, MOST RECENTLY, OMICRON VARIANTS FOLLOWED. EACH SUCCESSIVE WAVE OF THE CORONAVIRUS CAUSED DEATH AND DISRUPTION ACROSS THE GLOBE AND THREATENED TO DIMINISH THE EFFECTIVENESS OF NEWLY AVAILABLE COVID-19 VACCINES AND THERAPIES.THE URGENCY OF TRACKING AND STUDYING THESE VARIANTS BECAME PAINFULLY CLEAR. WHILE A VARIETY OF PLATFORMS WERE AND CONTINUE TO BE USED BY DIFFERENT COUNTRIES TO SEQUENCE AND SHARE VIRUS DATA, THE FNIH AND NIH RECOGNIZED EARLY ON THAT A COORDINATED, GLOBAL PERSPECTIVE IS ESSENTIAL TO UNDERSTAND THE EVOLUTION OF THE VIRUS AND THE IMPACT OF VARIANTS ON THERAPEUTICS AND VACCINES. IN JANUARY 2021, THE FNIH CONVENED GOVERNMENT AGENCIES, ACADEMICS, AND PRIVATE PARTNERS TO ESTABLISH THE ACTIV TRACKING RESISTANCE AND CORONAVIRUS EVOLUTION (TRACE) INITIATIVE. THROUGH GENOMIC SURVEILLANCE, DATA SHARING, AND ASSESSMENTS OF TREATMENT RESPONSES TO NEW VIRUS STRAINS, TRACE STANDARDIZES AND CONSOLIDATES DATA FROM GENETIC DATABASES WORLDWIDE TO MONITOR AND TEST COVID-19 VARIANTS. TRACE ALSO ASSESSES VACCINE AND THERAPEUTIC RESISTANCE AND EVALUATES THE IMPACT OF GENETIC VARIATION ON VIRAL BIOLOGY AND ON THE CLINICAL APPROACHES FOR PREVENTING AND TREATING ILLNESS. TRACE HAS SUCCESSFULLY COMPILED ALL OF THIS CRITICAL INFORMATION INTO ONE CLEAR, PUBLICLY ACCESSIBLE PLATFORM AT THE NIH'S NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES AND IS RAPIDLY SHARING DATA ON COVID-19 VARIANTS WITH THE ENTIRE GLOBAL SCIENTIFIC COMMUNITY. THE BESPOKE GENE THERAPY CONSORTIUMRARE DISEASES ARE DEFINED IN THE U.S. AS THOSE THAT AFFECT FEWER THAN 200,000 PEOPLE WITH SOME AFFLICTING AS FEW AS 10 INDIVIDUALS IN THE WORLD. BUT COLLECTIVELY THESE DISEASES ARE RESPONSIBLE FOR WIDESPREAD HARM. SOME 25 TO 30 MILLION AMERICANS, AS WELL AS THEIR FAMILIES AND COMMUNITIES, SUFFER FROM THE APPROXIMATELY 7,000 RARE DISEASES KNOWN TODAY, WITH FEW EFFECTIVE TREATMENTS. ONE TYPE OF TREATMENT HAS EMERGED THAT OFFERS HOPE: GENE THERAPY, A PROCESS THAT REPLACES DEFECTIVE GENES THAT CAUSE DISEASE WITH FUNCTIONAL ONES. WHILE GENE THERAPIES HAVE BEEN SUCCESSFULLY USED TO TREAT COMMON GENETIC DISEASES, THEY CAN ALSO BE TAILORED (OR "BESPOKE") FOR MUCH SMALLER POPULATIONS. DEVELOPING THESE THERAPIES, HOWEVER, IS COMPLEX AND OFTEN EXPENSIVE, AND SMALL PATIENT POPULATIONS MAKE IT CHALLENGING TO GET AN ADEQUATE RETURN ON INVESTMENT IN THE DEVELOPMENT PROCESS. THE BESPOKE GENE THERAPY CONSORTIUM (BGTC) PROMISES TO CHANGE THE PLAYING FIELD FOR GENE THERAPY DEVELOPMENT. LAUNCHED IN LATE 2021 BY THE FNIH, NIH, AND FDA, THE BGTC AIMS TO GENERATE A STANDARDIZED "PLUG-AND-PLAY" TEMPLATE THAT MAKES IT EASIER TO DEVELOP NEW GENE THERAPIES. RATHER THAN CREATING A CUSTOM THERAPY FOR EACH DISEASE FROM SCRATCH, DEVELOPERS COULD SOON BE ABLE TO USE AND REUSE THIS COMMON TEMPLATE TO PRODUCE THERAPIES MORE QUICKLY AND AT LOWER COST. THE BGTC IS THE LATEST INITIATIVE TO EMERGE FROM THE FNIH'S HIGHLY SUCCESSFUL ACCELERATING MEDICINES PARTNERSHIP (AMP) PROGRAM. BUILDING ON THE AMP COLLABORATION MODEL, THE BGTC PROGRAM BRINGS TOGETHER 30 PUBLIC AND PRIVATE SECTOR ORGANIZATIONS, INCLUDING MANY RARE DISEASE PATIENT GROUPS, TO SUPPORT A SERIES OF RESEARCH PROJECTS AND CLINICAL TRIALS INTENDED TO REFINE AND STANDARDIZE TRIAL DESIGN, REGULATORY EVALUATION, AND MANUFACTURING PROCESSES, ENABLING THE FIELD TO DELIVER MORE VIABLE TREATMENTS FOR RARE DISEASES TO MORE PATIENTS.ACCELERATING MEDICINES PARTNERSHIP (AMP) PROGRAMSTHE FNIH LAUNCHED THE FIRST THREE ACCELERATING MEDICINES PARTNERSHIP PROGRAMS TOGETHER WITH THE NIH IN 2014. FOCUSED ON ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND RHEUMATOID ARTHRITIS AND LUPUS, THE FIRST AMP PROGRAMS GENERATED GENOMIC AND MOLECULAR DATA AND ANALYTICAL APPROACHES THAT HAVE SUBSTANTIALLY ADVANCED OUR UNDERSTANDING OF DRUG TARGETS IN THESE DISEASES. THESE THREE PARTNERSHIPS HAVE PROVED SO SUCCESSFUL THAT EACH HAS NOT ONLY PRODUCED FOLLOW-ON EFFORTS THAT CONSIDERABLY EXPAND THEIR ORIGINAL RESEARCH AGENDAS, BUT THEY HAVE ALSO INSPIRED COMPLETELY NEW AMP PROGRAMS IN PARKINSON'S DISEASE, SCHIZOPHRENIA, AND GENE THERAPIES.ACCELERATING MEDICINES PARTNERSHIP AND AMP ARE REGISTERED SERVICE MARKS OF THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES.NON-INVASIVE BIOMARKERS OF METABOLIC LIVER DISEASE (NIMBLE)NON-ALCOHOLIC STEATOHEPATITIS (NASH) IS A SERIOUS LIVER DISEASE ESTIMATED TO AFFECT BETWEEN 9 AND 15 MILLION PEOPLE IN THE U.S. THE DISEASE OFTEN REMAINS UNDIAGNOSED IN ITS EARLY STAGES AND CAN REQUIRE A LIVER TRANSPLANT OR CAUSE LIVER CANCER AND ULTIMATELY DEATH. CURRENTLY, DIAGNOSING EARLY-STAGE NASH REQUIRES A LIVER BIOPSY, A PAINFUL, INVASIVE, AND EXPENSIVE PROCESS.IN NOVEMBER 2021, THE FNIH BIOMARKERS CONSORTIUM RELEASED THE INITIAL RESULTS FROM ITS NIMBLE PROJECT, WHICH SEEKS TO ASSESS THE SUITABILITY OF SEVERAL NON-INVASIVE, BLOOD-BASED BIOMARKERS FOR USE IN CLINICAL TRIALS OF TREATMENTS FOR NASH. SEVERAL OF THESE BIOMARKERS DID A BETTER JOB OF IDENTIFYING PATIENTS AT RISK OF DEVELOPING NASH OR PROGRESSING TO CIRRHOSIS THAN CURRENT STANDARD TESTS AND COMPARED FAVORABLY WITH THE DIAGNOSTIC PERFORMANCE OF LIVER BIOPSY, THE CURRENT REFERENCE STANDARD. ALTHOUGH FURTHER CONFIRMATORY STUDY MAY BE REQUIRED, THE NEW BIOMARKERS EXAMINED BY NIMBLE COULD POTENTIALLY REPLACE THE NEED FOR PATIENTS WHO HAVE OR WHO MAY BE AT RISK FOR NASH TO UNDERGO BIOPSIES. IF APPROVED BY THE FDA, TESTS USING THESE NEW MARKERS COULD ENABLE EARLY AND ACCURATE DIAGNOSIS OF AT-RISK PATIENTS, IMPROVING THE QUALITY OF CARE, ACCELERATING DRUG DEVELOPMENT, AND REDUCING THE BURDEN IMPOSED BY CURRENT CLINICAL CARE PRACTICES. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $1,310,343 | ExpenseAmt |
| Grant | $1,011,545 | GrantAmt |
| Desc | SEE SCHEDULE O, PROGRAM TWO, AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMSPROGRAM TWO - AWARDS, EVENTS, EDUCATION/TRAINING PROGRAMS - ONE OF THE MANY WAYS THE FNIH ACCELERATES PROGRESS IS THROUGH INVESTMENT IN THE CREATIVITY OF EXCEPTIONAL SCIENTISTS. THE ORGANIZATION BESTOWS THREE PRIZES EACH YEAR TO RECOGNIZE OUTSTANDING PARTNERS AND CONTRIBUTORS TO ADVANCING BIOMEDICAL RESEARCH. 2021 FNIH AWARDS THE LURIE PRIZE IN BIOMEDICAL SCIENCESTHE LURIE PRIZE IN BIOMEDICAL SCIENCES IS AN ANNUAL AWARD GIVEN TO PROMISING YOUNGER INVESTIGATORS WHO HAVE ACHIEVED GROUNDBREAKING ADVANCES IN BIOMEDICAL SCIENCE. THE PRIZE IS MADE POSSIBLE BY A GENEROUS GIFT FROM NOTED PHILANTHROPIST AND FNIH HONORARY BOARD MEMBER ANN LURIE. IN 2021, THE FNIH HONORED XIAOWEI ZHUANG, PH.D., FOR HER REVOLUTIONARY WORK DEVELOPING SUPER-RESOLUTION MICROSCOPY AND GENOME-SCALE IMAGING THAT REVEALED NEW SPATIAL AND FUNCTIONAL ORGANIZATIONS OF MOLECULES AND CELLS. DR. ZHUANG'S INNOVATIVE WORK WITH MICROSCOPY HAS ENABLED RESEARCHERS TO VISUALIZE WITH HIGH RESOLUTION THE POSITIONING OF AND INTERACTIONS BETWEEN MOLECULES IN A CELL, AS WELL AS THE SPATIAL ORGANIZATION OF DISTINCT TYPES OF CELLS IN TISSUES. HER DISCOVERIES HAVE MADE A SIGNIFICANT IMPACT ACROSS THE FIELD OF BIOLOGY, WITH SEMINAL APPLICATIONS TO CELL BIOLOGY.DR. ZHUANG IS A PROFESSOR AT HARVARD UNIVERSITY, A HOWARD HUGHES MEDICAL INSTITUTE INVESTIGATOR, AND CO-FOUNDER OF THE LIFE SCIENCES COMPANY VIZGEN.TRAILBLAZER PRIZE FOR CLINICIAN-SCIENTISTSTHE TRAILBLAZER PRIZE FOR CLINICIAN-SCIENTISTS WAS ESTABLISHED IN 2018 TO HIGHLIGHT THE ESSENTIAL ROLE OF EARLY CAREER CLINICIAN-SCIENTISTS WHOSE RESEARCH HAS LED OR HAS THE POTENTIAL TO LEAD TO INNOVATIONS IN PATIENT CARE.IN 2021, PIRO LITO, M.D., PH.D., ASSOCIATE MEMBER AND ATTENDING PHYSICIAN AT MEMORIAL SLOAN KETTERING CANCER CENTER, WAS AWARDED THE PRIZE FOR CATALYZING BREAKTHROUGHS IN THE UNDERSTANDING OF ONCOPROTEIN SIGNALING AND THE DEVELOPMENT OF NOVEL THERAPEUTIC APPROACHES FOR CANCERS DRIVEN BY THE MUTANT KRAS PROTEIN.WORKING AT THE INTERFACE OF BASIC RESEARCH AND CLINICAL PRACTICE, DR. LITO STUDIES HOW MUTATED PROTEINS DRIVE TUMOR GROWTH. HE IS PARTICULARLY INTERESTED IN A PROTEIN CALLED KRAS, WHICH IS COMMONLY MUTATED IN LUNG, COLORECTAL, AND PANCREATIC CANCERS. DR. LITO HAS UNCOVERED HOW MUTANT KRAS TRANSITIONS BETWEEN ITS ACTIVE AND INACTIVE STATES IN CANCER CELLS AND, BY EXPOSING VULNERABLE EVENTS DURING THIS TRANSITION, HE HAS MADE KEY CONTRIBUTIONS TO THE DEVELOPMENT OF NOVEL CANCER THERAPIES THAT ARE CURRENTLY IN CLINICAL TRIALS.FUNDING FOR THE TRAILBLAZER PRIZE IS PROVIDED BY THE GALLIN FUND AT THE FNIH.CHARLES A. SANDERS, M.D., PARTNERSHIP AWARDEACH YEAR, THE FNIH BESTOWS THE CHARLES A. SANDERS, M.D., PARTNERSHIP AWARD TO RECOGNIZE PEOPLE OR ORGANIZATIONS THAT HAVE MADE PARTICULARLY SIGNIFICANT CONTRIBUTIONS TO THE FOUNDATION'S EFFORTS TO BUILD, IMPLEMENT, AND NURTURE PUBLIC-PRIVATE PARTNERSHIPS IN SUPPORT OF THE MISSION OF THE NIH.IN 2021, THE FNIH PRESENTED THE PARTNERSHIP AWARD TO JANSSEN RESEARCH & DEVELOPMENT, LLC, AND TO THE EIGHT CO-CHAIRS OF THE ACCELERATING COVID-19 THERAPEUTIC INTERVENTIONS AND VACCINES (ACTIV) WORKING GROUPS.JANSSEN RESEARCH & DEVELOPMENT, LLC, HAS BEEN AN EXEMPLARY PARTNER AND LEADER ACROSS MANY FNIH PROGRAMS, INCLUDING ACTIV, SEVERAL ACCELERATING MEDICINES PARTNERSHIPS, THE BIOMARKERS CONSORTIUM, THE PARTNERSHIP FOR ACCELERATING CANCER THERAPIES (PACT), AND THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI). THE MANY JANSSEN SCIENTISTS WHO HAVE PARTICIPATED IN THESE PARTNERSHIPS HAVE CONSISTENTLY PROMOTED A HIGHLY COLLEGIAL, COLLABORATIVE APPROACH TO PROBLEM-SOLVING WITH AN EMPHASIS ON TEAMWORK AND TRANSPARENT COMMUNICATION THAT ENABLES OPEN, PRECOMPETITIVE SCIENCE.IN SUPPORT OF FINDING THERAPEUTICS AND VACCINES TO COMBAT COVID-19, THE ACTIV WORKING GROUP CO-CHAIRS SPENT COUNTLESS HOURS COLLABORATING WITH THE FNIH AND NIH TO DESIGN STRATEGIES FOR COMBATING THE COVID-19 PANDEMIC AND EXECUTE THEM WITH UNPRECEDENTED SPEED. THEY PARTICIPATED IN HUNDREDS OF MEETINGS, REPORTING REGULARLY TO THE ACTIV LEADERSHIP TEAM, AND DEVOTED VALUABLE TIME AND EFFORT TO IDENTIFY OPPORTUNITIES FOR AND HELP RESOLVE CHALLENGES TO THE PARTNERSHIP. THEIR ALL-OUT EFFORTS WERE ESSENTIAL TO ENABLING ACTIV TO NAVIGATE THE RAPIDLY CHANGING NATURE OF THE THREATS TO GLOBAL HUMAN HEALTH POSED BY SARS-COV-2.THE CO-CHAIRS OF THE ACTIV WORKING GROUPS:CHRISTINE M. COLVIS, PH.D., DIRECTOR OF DRUG DEVELOPMENT PARTNERSHIP PROGRAMS, NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS) AT NIHELIZABETH DESROSIERS, M.S., P.M.P., EXECUTIVE DIRECTOR OF CLINICAL SCIENCES AND STUDY MANAGEMENT AT MERCK & CO., INC.ERIC HUGHES, M.D., PH.D., GLOBAL DEVELOPMENT UNIT HEAD OF IMMUNOLOGY, HEPATOLOGY AND DERMATOLOGY, AND CHI-NOVARTISKATHRIN JANSEN, PH.D., SENIOR VICE PRESIDENT AND HEAD OF VACCINE RESEARCH AND DEVELOPMENT AT PFIZERMICHAEL KURILLA, M.D., PH.D., DIRECTOR, DIVISION OF CLINICAL INNOVATION, NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS) AT NIHDOUGLAS LOWY, M.D., PRINCIPAL DEPUTY DIRECTOR, NATIONAL CANCER INSTITUTE (NCI) AT NIHSARAH READ, M.D., DEPUTY DIRECTOR, DIVISION OF AIDS, NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) AT NIH JOHN YOUNG, PH.D., GLOBAL HEAD OF INFECTIOUS DISEASES AND VICE PRESIDENT AT ROCHEFUNDING FOR THE CHARLES A. SANDERS, M.D., PARTNERSHIP AWARD IS PROVIDED BY THE CHARLES A. SANDERS LEGACY FUND AT THE FNIH.EVENTS AND EDUCATIONTHE MEETINGS AND EVENTS DEPARTMENT CONCEPTUALIZES, PLANS, EXECUTES AND EVALUATES HIGH-QUALITY, PRODUCTIVE, INNOVATIVE AND ECONOMICAL CONVENINGS THAT ADVANCE THE ORGANIZATION'S MISSION. THESE CONVENINGS INCLUDE, BUT ARE NOT LIMITED TO, RESEARCH PROJECT TEAM MEETINGS AND CONFERENCES, DONOR STEWARDSHIP LECTURES AND SYMPOSIA AND SPECIAL EVENTS. THE DEPARTMENT OVERSEES THE MANAGEMENT OF FNIH HIGHLY RESPECTED AWARDS AND PRIZES. SOME OF THE FNIH'S MARQUEE EVENTS IN 2021 INCLUDED: THE FNIH AWARDS CEREMONY, THE CANCER STEERING COMMITTEE'S ANNUAL SYMPOSIUM, AND THE GENECONVENE GLOBAL COLLABORATIVE WEBINARS SERIES.THE FNIH SUPPORTS A NUMBER OF EDUCATIONAL AND TRAINING OPPORTUNITIES AT NIH, RANGING FROM HIGH SCHOOL TO POSTGRADUATE FELLOWSHIPS AND TRAINING. MANY OF THESE FELLOWSHIPS AND TRAININGS ARE ESTABLISHED BY INDIVIDUALS WHO SEEK TO SUPPORT THE NEXT GENERATION OF SCIENTISTS. EXAMPLES INCLUDE:- THE JAYNE KOSKINAS TED GIOVANIS FOUNDATION FOR HEALTH AND POLICY SUPPORTS INTRAMURAL RESEARCH TRAINING AWARDS FOR DESERVING YOUNG SCHOLARS IN THE NIH INTRAMURAL TRAINING PROGRAM.- THE DEAN R. O'NEILL RENAL CELL CANCER RESEARCH FUND AND THE DR. EDWARD T. RANCIC MEMORIAL FUND FOR CANCER RESEARCH JOINTLY SUPPORT A FELLOW IN THE LABORATORY OF DR. RICHARD CHILDS AT THE NATIONAL HEART, LUNG, AND BLOOD INSTITUTE TO EXPLORE TREATMENTS FOR RENAL CELL CARCINOMA.- THE ESTATE OF SALLIE ROSEN KAPLAN ESTABLISHED THE SALLIE ROSEN KAPLAN POSTDOCTORAL FELLOWSHIP FOR WOMEN SCIENTISTS IN CANCER RESEARCH (SRK FELLOWSHIP). THE SRK FELLOWSHIP IS A HIGHLY COMPETITIVE, UNPAID, ANNUAL, ONE-YEAR PROGRAM THAT PROVIDES ADDITIONAL MENTORING OPPORTUNITIES, NETWORKING, SEMINARS AND WORKSHOPS TO FEMALE NATIONAL CANCER INSTITUTE POSTDOCTORAL FELLOWS TO HELP THEM PREPARE FOR THE COMPETITIVE JOB MARKET AND HELP THEM TO TRANSITION TO INDEPENDENT RESEARCH CAREERS. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $53,512 | ExpenseAmt |
| Grant | $0 | GrantAmt |
| Revenue | $0 | RevenueAmt |
| Desc | SEE SCHEDULE O, PROGRAM THREE, PATIENT SUPPORT PROGRAM/CAPITAL PROJECTPROGRAM THREE - PATIENT SUPPORT PROGRAM/CAPITAL PROJECT -FILLING A NEED OF THE NATION'S LEADING RESEARCH CENTERAT THE NIH CLINICAL CENTER THE NATION'S PREMIER HOSPITAL SOLELY DEVOTED TO CLINICAL INVESTIGATION PATIENTS ARE CONSIDERED "ACTIVE PARTNERS IN MEDICAL DISCOVERY," PARTICIPATING IN EXPERIMENTAL TRIALS CARRIED OUT BY NIH INSTITUTES TO RECEIVE TREATMENT FOR THEIR CONDITIONS AND ULTIMATELY BENEFIT SCIENTIFIC PROGRESS. THE EXTENSIVE LIST OF RESEARCH BREAKTHROUGHS COMING OUT OF THE NIH CLINICAL CENTER INCLUDES THE FIRST CURES FOR CHILDHOOD LEUKEMIA AND HODGKIN'S DISEASE USING CHEMOTHERAPY, THE FIRST BLOOD TESTS FOR AIDS AND HEPATITIS, AND THE FIRST GENE THERAPY, TO NAME JUST A FEW. TO SUPPORT SUCH RESOURCE-INTENSIVE ENDEAVORS, THE FNIH ESTABLISHED THE CLINICAL CENTER IN-KIND DRUG DONATION PROGRAM TO DONATE PHARMACEUTICALS TO THE NIH CLINICAL CENTER. THE PROGRAM, WHICH HAS PROVIDED NEARLY $16 MILLION IN DRUGS AND THERAPEUTICS TO THE NIH SINCE 2008, WAS SUPPORTED IN 2019 BY A MAJOR GIFT FROM HORIZON THERAPEUTICS PLC. "THE GENEROSITY OF THE PROGRAM HAS BEEN A MAJOR BOON TO OUR PATIENTS AND OUR PROGRAM," SAYS DR. STEVEN HOLLAND, DIRECTOR, DIVISION OF INTRAMURAL RESEARCH AT NIAID. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Expenses | $51,956,043 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (1) | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | Yes (1) | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | Yes (1) | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | Yes (1) | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (1) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | Yes (1) | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | 0 | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | 0 | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | Yes (1) | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | Yes (1) | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | 0 | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | Yes (1) | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | 0 | RelatedEntityInd |
| Related Organization Ctrl Ent | 0 | RelatedOrganizationCtrlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 35 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 86 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | Yes (1) | QuidProQuoContributionsInd |
| Quid Pro Quo Contri Discl | Yes (1) | QuidProQuoContriDisclInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | 0 | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 24 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 24 | IndependentVotingMemberCnt |
| Family Or Business Rln | Yes (1) | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | Yes (1) | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | 0 | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | GA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | HI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NM | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | RI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | SC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | UT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WV | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WI | StatesWhereCopyOfReturnIsFldCd |
| Own Website | Yes (X) | OwnWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | DONALD M HILL | PersonNm |
| Phone | 3014356246 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 11400 ROCKVILLE PIKE SUITE 600 | AddressLine1Txt |
| City | NORTH BETHESDA | CityNm |
| State Abbreviation | MD | StateAbbreviationCd |
| ZIP | 20852 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (39 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|
| DR STEVEN M PAUL | ||||||||
| CHAIRMAN | 1.50 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| DR SOLOMON H SNYDER | ||||||||
| VICE-CHAIRMAN | 0.50 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| MR STEVEN C MAYER | ||||||||
| TREASURER | 2.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| MRS WILLIAM MCCORMICK BLAIR JR | ||||||||
| SECRETARY | 1.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| DR MARIA C FREIRE UNTIL SEPT | ||||||||
| PRESIDENT & EXECUTIVE DIRECTOR | 40.00 | Yes (X) | Yes (X) | $458,587 | $0 | $23,200 | ||
| DR KATHY BLOOMGARDEN | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR MARIJN DEKKERS | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| MR JAMES H DONOVAN | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR PAUL L HERRLING | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR THOMAS R INSEL | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR JUDY LANSING KOVLER | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR RONALD L KRALL | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR FREDA LEWIS-HALL | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| JULIE BELL LINDSAY | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR EDISON T LIU | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| MR JOEL S MARCUS | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DAME JILLIAN SACKLER | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| MRS LILY SAFRA | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR CHARLES A SANDERS | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| MR FRED SEIGEL | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR ELLEN V SIGAL | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| MR RUSSELL W STEENBERG | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DR PAUL STOFFELS | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| ELIAS ZERHOUNI | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| GILBERT S OMENN | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| MRS WILLIAM M CAFRITZ UNTIL MAY | ||||||||
| BOARD OF DIRECTORS MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |||
| DAVID WHOLLEY FROM SEPT | ||||||||
| INTERIM PRES. & EXECUTIVE DIRECTOR | 40.00 | Yes (X) | $415,304 | $0 | $38,260 | |||
| DONALD HILL | ||||||||
| CHIEF FINANCIAL OFFICER | 40.00 | Yes (X) | $264,990 | $0 | $36,642 | |||
| KEVIN A KLOCK | ||||||||
| VP OF OPERATIONS & GENERAL COUNSEL | 40.00 | Yes (X) | $236,844 | $0 | $34,800 | |||
| STEPHANIE JAMES | ||||||||
| SENIOR SCIENTIFIC ADVISOR | 40.00 | $285,699 | $0 | $22,463 | Yes (X) | |||
| MICHAEL SANTOS | ||||||||
| VICE PRESIDENT OF SCIENCE | 40.00 | $341,916 | $0 | $30,380 | Yes (X) | |||
| JULIE WOLF-RODDA | ||||||||
| SENIOR VP OF DEVELOPMENT | 40.00 | $248,167 | $0 | $34,493 | Yes (X) | |||
| JOSEPH MENETSKI | ||||||||
| VP, RESEARCH PARTNERSHIPS | 40.00 | $270,098 | $0 | $34,092 | Yes (X) | |||
| ROBERT BALTHASER | ||||||||
| VICE PRESIDENT OF ADVANCEMENT | 40.00 | $171,092 | $0 | $20,719 | Yes (X) | |||
| STACEY ADAM | ||||||||
| ASSOCIATE VP, RESEARCH PARTNERSHIPS | 40.00 | $235,835 | $0 | $25,932 | Yes (X) | |||
| DAVID O'BROCHTA | ||||||||
| SCIENTIFIC PROGRAM MANAGER | 40.00 | $195,268 | $0 | $31,019 | Yes (X) | |||
| KAREN TOUNTAS | ||||||||
| SCIENTIFIC PROGRAM MANAGER | 40.00 | $193,750 | $0 | $22,492 | Yes (X) | |||
| BRINDA DASS | ||||||||
| SCIENTIFIC PROGRAM MANAGER | 40.00 | $188,862 | $0 | $24,049 | Yes (X) | |||
| STEVEN HOFFMANN | ||||||||
| ASSOCIATE VP, RESEARCH PARTNERSHIPS | 40.00 | $187,977 | $0 | $27,608 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $3,694,389 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $406,149 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 34 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| SWOG CTI | |||||
| 24 FRANK LLOYD WRIGHT DRIVE PO BOX | ANN ARBOR | MI | 48105 | CLINICAL TRIAL FOR LUNG MAP PROJECT | $6,280,530 |
| DANA-FARBER CANCER INSTITUTE | |||||
| 450 BROOKLINE AVENUE | BOSTON | MA | 02215 | THE PACT & CTDNA RESEARCH COLLABORATION | $2,521,758 |
| DELOITTE CONSULTING LLP | |||||
| 4022 SELLS DRIVE | HERMITAGE | TN | 37076 | COVID-19 PROJECT PROFESSIONAL SERVICES | $2,382,326 |
| THE UNIVERSITY OF TEXASMD ANDERSON | |||||
| PO BOX 4266 | HOUSTON | TX | 77210 | THE PACT PROJECT RESEARCH COLLABORATION | $905,317 |
| THE BROAD INSTITUTE INC | |||||
| 415 MAIN STREET | CAMBRIDGE | MA | 02142 | THE CHIIME PROJECT RESEARCH COLLABORATIO | $884,421 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 32 | CntrctRcvdGreaterThan100KCnt |
| Fundraising | $60,500 | FundraisingAmt |
| Government Grants | $1,250,000 | GovernmentGrantsAmt |
| All Other Contributions | $104,683,285 | AllOtherContributionsAmt |
| Noncash Contributions | $3,684,256 | NoncashContributionsAmt |
| Total Contributions | $105,993,785 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | ADMINISTRATIVE REVENUE | Desc |
| Business | 900099 | BusinessCd |
| Total Revenue Column | $50,000 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $50,000 | RelatedOrExemptFuncIncomeAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $50,000 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $1,346,882 | TotalRevenueColumnAmt |
| Exclusion | $1,346,882 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $11,955,373 | SecuritiesAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $11,778,361 | SecuritiesAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $177,012 | SecuritiesAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $177,012 | TotalRevenueColumnAmt |
| Exclusion | $177,012 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fundraising Gross Income | $291,800 | FundraisingGrossIncomeAmt |
| Contri Rpt Fundraising Event | $60,500 | ContriRptFundraisingEventAmt |
| Fundraising Direct Expenses | $253,788 | FundraisingDirectExpensesAmt |
Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $38,012 | TotalRevenueColumnAmt |
| Exclusion | $38,012 | ExclusionAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $107,605,691 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $50,000 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $1,561,906 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $20,124,066 | TotalAmt |
| Program Services | $20,124,066 | ProgramServicesAmt |
Grants To Domestic Individuals GrantsToDomesticIndividualsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,500 | TotalAmt |
| Program Services | $3,500 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $798,005 | TotalAmt |
| Program Services | $798,005 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,967,746 | TotalAmt |
| Program Services | $1,436,567 | ProgramServicesAmt |
| Management And General | $1,482,419 | ManagementAndGeneralAmt |
| Fundraising | $48,760 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $5,868,953 | TotalAmt |
| Program Services | $3,971,368 | ProgramServicesAmt |
| Management And General | $1,897,585 | ManagementAndGeneralAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $514,483 | TotalAmt |
| Program Services | $309,430 | ProgramServicesAmt |
| Management And General | $195,960 | ManagementAndGeneralAmt |
| Fundraising | $9,093 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,231,077 | TotalAmt |
| Program Services | $781,689 | ProgramServicesAmt |
| Management And General | $434,363 | ManagementAndGeneralAmt |
| Fundraising | $15,025 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $618,512 | TotalAmt |
| Program Services | $317,744 | ProgramServicesAmt |
| Management And General | $300,768 | ManagementAndGeneralAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $190,081 | TotalAmt |
| Program Services | $87,892 | ProgramServicesAmt |
| Management And General | $102,189 | ManagementAndGeneralAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $183,504 | TotalAmt |
| Management And General | $183,504 | ManagementAndGeneralAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $33,712 | TotalAmt |
| Program Services | $27,813 | ProgramServicesAmt |
| Management And General | $5,899 | ManagementAndGeneralAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $10,468 | TotalAmt |
| Program Services | $5,871 | ProgramServicesAmt |
| Management And General | $4,597 | ManagementAndGeneralAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $121,563 | TotalAmt |
| Program Services | $44,439 | ProgramServicesAmt |
| Management And General | $56,938 | ManagementAndGeneralAmt |
| Fundraising | $20,186 | FundraisingAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $735,559 | TotalAmt |
| Program Services | $179,582 | ProgramServicesAmt |
| Management And General | $555,977 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $140,390 | TotalAmt |
| Program Services | $134,401 | ProgramServicesAmt |
| Management And General | $5,989 | ManagementAndGeneralAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $240,478 | TotalAmt |
| Management And General | $240,478 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $228,032 | TotalAmt |
| Program Services | $135,102 | ProgramServicesAmt |
| Management And General | $92,930 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt | FundraisingFundraisingAmt |
|---|---|---|---|---|
| PROGRAM CONTRACTS | $19,091,057 | $19,078,577 | $12,480 | |
| CONSULTANTS | $4,655,198 | $4,311,705 | $326,029 | $17,464 |
| RECRUITING | $379,759 | $30,625 | $349,134 | |
| HONORARIA | $112,000 | $112,000 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $154,493 | TotalAmt |
| Program Services | $65,667 | ProgramServicesAmt |
| Management And General | $87,084 | ManagementAndGeneralAmt |
| Fundraising | $1,742 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $58,402,636 | TotalAmt |
| Program Services | $51,956,043 | ProgramServicesAmt |
| Management And General | $6,334,323 | ManagementAndGeneralAmt |
| Fundraising | $112,270 | FundraisingAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $66,486,739 | BOYAmt |
| EOY | $47,993,053 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $41,358,911 | BOYAmt |
| EOY | $67,125,693 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $235,751 | BOYAmt |
| EOY | $230,354 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $2,965,720 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $1,239,951 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,948,833 | BOYAmt |
| EOY | $1,725,769 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $59,636,280 | BOYAmt |
| EOY | $101,529,635 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,273,227 | BOYAmt |
| EOY | $3,335,255 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $171,939,741 | BOYAmt |
| EOY | $221,939,759 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,166,950 | BOYAmt |
| EOY | $8,537,356 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,331,478 | BOYAmt |
| EOY | $338,978 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,237,097 | BOYAmt |
| EOY | $2,114,103 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $10,735,525 | BOYAmt |
| EOY | $10,990,437 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $25,368,465 | BOYAmt |
| EOY | $28,544,211 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $135,835,751 | BOYAmt |
| EOY | $182,405,111 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $161,204,216 | BOYAmt |
| EOY | $210,949,322 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $171,939,741 | BOYAmt |
| EOY | $221,939,759 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | $49,203,055 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | $542,051 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Info In Schedule O Part XII | Yes (X) | InfoInScheduleOPartXIIInd |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Separate Basis Fincl Stmt | Yes (X) | SeparateBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (1) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (1) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $61,322,159 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $60,444,618 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $50,623,645 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $98,343,956 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $105,993,785 | CurrentTaxYearAmt |
| Total | $376,728,163 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $61,322,159 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $60,444,618 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $50,623,645 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $98,343,956 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $105,993,785 | CurrentTaxYearAmt |
| Total | $376,728,163 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $145,478,494 | SubstantialContributorsTotAmt |
| Public Support Total170 | $231,249,669 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $1,066,052 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $2,057,158 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $2,818,334 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $1,722,957 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $1,346,882 | CurrentTaxYearAmt |
| Total | $9,011,383 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $385,739,546 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $176,383 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.59950 | PublicSupportCY170Pct |
| Public Support PY170 | 0.57280 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
| Field | Value | IRS element (for citing) |
|---|---|---|
| Volunteers | 0 | VolunteersInd |
| Paid Staff Or Management | Yes (1) | PaidStaffOrManagementInd |
| Media Advertisements | 0 | MediaAdvertisementsInd |
| Mailings Members | 0 | MailingsMembersInd |
| Publications Or Broadcast | 0 | PublicationsOrBroadcastInd |
| Grants Other Organizations | 0 | GrantsOtherOrganizationsInd |
| Direct Contact Legislators | Yes (1) | DirectContactLegislatorsInd |
| Rallies Demonstrations | 0 | RalliesDemonstrationsInd |
| Other Activities | 0 | OtherActivitiesInd |
| Total Lobbying Expenditures | $0 | TotalLobbyingExpendituresAmt |
| Not Described Section501c3 | 0 | NotDescribedSection501c3Ind |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART II-B, LINE 1: | FormAndLineReferenceDesc |
| Explanation | FNIH CONSULTED ITS CONGRESSIONAL COMMITTEES OF JURISDICTION ON PUBLIC HEALTH LEGISLATION. | ExplanationTxt |
Schedule D IRS990ScheduleD
| Field | Value | IRS element (for citing) |
|---|---|---|
| Donor Advised Funds Held | 1 | DonorAdvisedFundsHeldCnt |
| Donor Advised Funds Contri | $2,700 | DonorAdvisedFundsContriAmt |
| Donor Advised Funds Grants | $14,951 | DonorAdvisedFundsGrantsAmt |
| Donor Advised Funds Vl EOY | $258,599 | DonorAdvisedFundsVlEOYAmt |
| Disclosed Org Leg Ctrl | Yes (1) | DisclosedOrgLegCtrlInd |
| Disclosed For Charitable Prps | Yes (1) | DisclosedForCharitablePrpsInd |
| Agent Trustee Etc | 0 | AgentTrusteeEtcInd |
| Incl Escrow Custodial Acct Liab | 0 | InclEscrowCustodialAcctLiabInd |
CY Endwmt Fund CYEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $20,878,035 | BeginningYearBalanceAmt |
| Contributions | $3,154,350 | ContributionsAmt |
| Investment Earnings Or Losses | $544,664 | InvestmentEarningsOrLossesAmt |
| Administrative Expenses | $65,915 | AdministrativeExpensesAmt |
| End Year Balance | $24,511,134 | EndYearBalanceAmt |
CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $14,897,505 | BeginningYearBalanceAmt |
| Contributions | $5,648,998 | ContributionsAmt |
| Investment Earnings Or Losses | $419,982 | InvestmentEarningsOrLossesAmt |
| Administrative Expenses | $88,450 | AdministrativeExpensesAmt |
| End Year Balance | $20,878,035 | EndYearBalanceAmt |
CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $12,514,811 | BeginningYearBalanceAmt |
| Contributions | $1,788,682 | ContributionsAmt |
| Investment Earnings Or Losses | $705,900 | InvestmentEarningsOrLossesAmt |
| Administrative Expenses | $111,888 | AdministrativeExpensesAmt |
| End Year Balance | $14,897,505 | EndYearBalanceAmt |
CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $11,920,726 | BeginningYearBalanceAmt |
| Contributions | $1,032,217 | ContributionsAmt |
| Investment Earnings Or Losses | -$267,231 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $103,397 | OtherExpendituresAmt |
| Administrative Expenses | $67,504 | AdministrativeExpensesAmt |
| End Year Balance | $12,514,811 | EndYearBalanceAmt |
CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $9,704,030 | BeginningYearBalanceAmt |
| Contributions | $1,721,204 | ContributionsAmt |
| Investment Earnings Or Losses | $552,828 | InvestmentEarningsOrLossesAmt |
| Administrative Expenses | $57,336 | AdministrativeExpensesAmt |
| End Year Balance | $11,920,726 | EndYearBalanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Board Designated Balance EOY | 0.76238 | BoardDesignatedBalanceEOYPct |
| Prmnnt Endowment Balance EOY | 0.23762 | PrmnntEndowmentBalanceEOYPct |
| Endowments Held Unrelated Org | 0 | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | 0 | EndowmentsHeldRelatedOrgInd |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $1,869,159 | OtherCostOrOtherBasisAmt |
| Depreciation | $460,471 | DepreciationAmt |
| Book Value | $1,408,688 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $1,096,561 | OtherCostOrOtherBasisAmt |
| Depreciation | $779,480 | DepreciationAmt |
| Book Value | $317,081 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $1,725,769 | TotalBookValueLandBuildingsAmt |
Other Liabilities Org OtherLiabilitiesOrgGrp (3 entries)
| DescDesc | AmtAmt |
|---|---|
| CHARITABLE GIFT ANNUITY | $119,864 |
| DEFERRED LEASE INCENTIVE | $1,408,688 |
| DEFERRED RENT LIABILITY | $585,551 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Liability | $2,114,103 | TotalLiabilityAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $108,512,594 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | $542,051 | NetUnrealizedGainsInvstAmt |
| Donated Services And Use Fclts | $294,568 | DonatedServicesAndUseFcltsAmt |
| Revenue Not Reported | $836,619 | RevenueNotReportedAmt |
| Revenue Subtotal | $107,675,975 | RevenueSubtotalAmt |
| Investment Expenses Not Incld | $183,504 | InvestmentExpensesNotIncldAmt |
| Other Revenues Not Included | -$253,788 | OtherRevenuesNotIncludedAmt |
| Revenue Not Reported Fincl Stmt | -$70,284 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $107,605,691 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $58,767,488 | TotExpnsEtcAuditedFinclStmtAmt |
| Donated Services Use Fclts | $294,568 | DonatedServicesUseFcltsAmt |
| Other Expenses Included | $253,788 | OtherExpensesIncludedAmt |
| Expenses Not Reported | $548,356 | ExpensesNotReportedAmt |
| Expenses Subtotal | $58,219,132 | ExpensesSubtotalAmt |
| Investment Expenses Not Incld2 | $183,504 | InvestmentExpensesNotIncld2Amt |
| Expenses Not Rpt Fincl Stmt | $183,504 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $58,402,636 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail (4 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART V, LINE 4: | THE FOUNDATION HAS ONE ENDOWMENT THAT IS FUNDED BY MULTIPLE DONORS TO SEED NEW DISCOVERIES AND/OR BE AVAILABLE TO RESPOND TO EPIDEMICS AND FOUNDATION'S UNANTICIPATED NEEDS. THE FOUNDATION'S OTHER ENDOWMENTS CONSIST OF INDIVIDUAL DONOR-RESTRICTED ENDOWMENT FUNDS ESTABLISHED FOR A VARIETY OF PURPOSE. (E.G. VARIETY OF RESEARCH AND EDUCATIONAL INITIATIVES AT THE FOUNDATION FOR THE NIH, INC). NET ASSETS ASSOCIATED WITH ENDOWMENT FUNDS ARE CLASSIFIED AND REPORTED BASED ON THE EXISTENCE OR ABSENCE OR DONOR-IMPOSED RESTRICTIONS. |
| PART X, LINE 2: | THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE; ACCORDINGLY, THE ACCOMPANYING FINANCIAL STATEMENTS DO NOT REFLECT A PROVISION OR LIABILITY FOR FEDERAL AND STATE INCOME TAXES. THE FOUNDATION HAS DETERMINED THAT IT DOES NOT HAVE ANY MATERIAL UNRECOGNIZED TAX BENEFITS OR OBLIGATIONS AS OF DECEMBER 31, 2021 AND 2020. |
| PART XI, LINE 4B - OTHER ADJUSTMENTS: | FUNDRAISING DIRECT EXPENSE -253,788. |
| PART XII, LINE 2D - OTHER ADJUSTMENTS: | FUNDRAISING DIRECT EXPENSE 253,788. |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (4 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|
| EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM | 0 | 0 | GRANTMAKING | $418,164 |
| EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, | 0 | 0 | GRANTMAKING | $19,892 |
| SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, | 0 | 0 | GRANTMAKING | $319,949 |
| NORTH AMERICA - CANADA | 0 | 0 | GRANTMAKING | $40,000 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 0 | SubtotalEmployeesCnt |
| Continuation Total Office | 0 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 0 | ContinuationTotalEmployeeCnt |
| Total Office | 0 | TotalOfficeCnt |
| Total Employee | 0 | TotalEmployeeCnt |
| Subtotal Spent | $798,005 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $798,005 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (5 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt | Non Cash AssistanceNonCashAssistanceAmt |
|---|---|---|---|---|
| SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, | RESEARCH | $90,523 | WIRE TRANSFER | $0 |
| SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, | RESEARCH | $229,426 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, | RESEARCH | $19,892 | WIRE TRANSFER | $0 |
| EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM | RESEARCH | $418,164 | WIRE TRANSFER | $0 |
| NORTH AMERICA | RESEARCH | $40,000 | WIRE TRANSFER | $0 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 1 | Total501c3OrgCnt |
| Total Other Org | 4 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | 0 | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | 0 | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 2: | PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS SOME DEVELOPING COUNTRY INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. |
| PART III ACCOUNTING METHOD: |
Schedule G IRS990ScheduleG
Fundraising Event Information FundraisingEventInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Event1 | 2021 FNIH AWARD CEREMONY | Event1Nm |
| Gross Receipts Event1 | $352,300 | GrossReceiptsEvent1Amt |
| Charitable Contri Event1 | $60,500 | CharitableContriEvent1Amt |
| Gross Revenue Event1 | $291,800 | GrossRevenueEvent1Amt |
| Food And Beverage Event1 | $369 | FoodAndBeverageEvent1Amt |
| Other Direct Expenses Event1 | $228,081 | OtherDirectExpensesEvent1Amt |
| Event2 | 2022 FNIH AWARD CEREMONY | Event2Nm |
| Other Direct Expenses Event2 | $25,338 | OtherDirectExpensesEvent2Amt |
| Gross Receipts Total | $352,300 | GrossReceiptsTotalAmt |
| Charitable Contributions Tot | $60,500 | CharitableContributionsTotAmt |
| Gross Revenue Total Events | $291,800 | GrossRevenueTotalEventsAmt |
| Food And Beverage Total Events | $369 | FoodAndBeverageTotalEventsAmt |
| Oth Direct Expnss Total Events | $253,419 | OthDirectExpnssTotalEventsAmt |
| Direct Expense Summary Events | $253,788 | DirectExpenseSummaryEventsAmt |
| Net Income Summary | $38,012 | NetIncomeSummaryAmt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (29 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Non Cash AssistanceNonCashAssistanceAmt | Purpose Of GrantPurposeOfGrantTxt | Address Line2USAddress/AddressLine2Txt |
|---|---|---|---|---|---|---|---|---|---|
| NIHCC - CLINICAL CENTER | |||||||||
| 9000 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 170(C)(1) GOVERNMENT | $346,545 | $0 | RESEARCH | |
| NIHNICCH | |||||||||
| 9000 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 170(C)(1) GOVERNMENT | $60,000 | $0 | RESEARCH | |
| NIHNCI | |||||||||
| 9000 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 170(C)(1) GOVERNMENT | $2,139,264 | $0 | RESEARCH | |
| NIHNIAID | |||||||||
| 9000 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 170(C)(1) GOVERNMENT | $4,937,710 | $0 | RESEARCH | |
| NIHNIAMS | |||||||||
| 9000 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 170(C)(1) GOVERNMENT | $2,300,000 | $0 | RESEARCH | |
| NIHNINDS | |||||||||
| 9000 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 170(C)(1) GOVERNMENT | $751,962 | $0 | RESEARCH | |
| NIH NHLBI | |||||||||
| 9000 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 170(C)(1) GOVERNMENT | $69,580 | $0 | RESEARCH | |
| NIHOD | |||||||||
| 9000 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 170(C)(1) GOVERNMENT | $262,000 | $0 | RESEARCH | |
| NIH NIMH | |||||||||
| 9000 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 170(C)(1) GOVERNMENT | $4,527,895 | $0 | RESEARCH | |
| NIHNIMHD | |||||||||
| 9000 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 170(C)(1) GOVERNMENT | $73,330 | $0 | RESEARCH | |
| NIHNIDA | |||||||||
| 9000 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 170(C)(1) GOVERNMENT | $95,000 | $0 | RESEARCH | |
| REGENTS OF THE UOF CALIFORNIASAN FRANCISCO | |||||||||
| MISSION HALL 550 16TH STREET 2ND | SAN FRANCISCO | CA | 94143 | 946036493 | 501(C)(3) | $17,577 | $0 | RESEARCH | FLOOR |
| RESEARCH TRIANGLE INSTITUTE | |||||||||
| PO BOX 900002 | RALEIGH | NC | 27675 | 560686338 | 501(C)(3) | $345,540 | $0 | RESEARCH | |
| UNIVERSITY OF ALABAMA AT BIRMINGHAM | |||||||||
| DEPT OF PEDIATRIC ADMIN LOWDER BLDG | BIRMINGHAM | AL | 35233 | 636001138 | 501(C)(3) | $71,718 | $0 | RESEARCH | 608 1600 7TH AVENUE SOUTH |
| THOMAS JEFFERSON UNIVERSITY | |||||||||
| 125 SOUTH 9TH STREET 2ND FLOOR | PHILADELPHIA | PA | 19107 | 231352651 | 501(C)(3) | $186,513 | $0 | RESEARCH | SHERIDAN BUILDING |
| EMORY UNIVERSITY | |||||||||
| PO BOX 935084 | ATLANTA | GA | 31193 | 580566256 | 501(C)(3) | $357,570 | $0 | RESEARCH | |
| GEORGETOWN UNIVERSITY | |||||||||
| 37TH AND O STREETS NW BOX 571173 | WASHINGTON | DC | 20057 | 530196603 | 501(C)(3) | $15,166 | $0 | RESEARCH | |
| NORTH CAROLINA STATE UNIVERSITY - UNIVERSITY OF NORTH CAROLINA CHAPEL HILL | |||||||||
| 104 AIRPORT DRIVE SUITE 2200 CAMPUS | CHAPEL HILL | NC | 27599 | 800543561 | 501(C)(3) | $147,835 | $0 | RESEARCH | BOX 1350 |
| THE TRUSTEES OF COLUMBIA UNIVERSITY | |||||||||
| PO BOX 29789 GENERAL POST OFFICE | NEW YORK | NY | 10087 | 135598093 | 501(C)(3) | $401,733 | $0 | RESEARCH | |
| TRUSTEES OF INDIANA UNIVERSITY | |||||||||
| THE POPLARS BUILDING400 E SEVENTH | BLOOMINGTON | IN | 47405 | 356001673 | 501(C)(3) | $140,303 | $0 | RESEARCH | ST |
| UNIVERSITY OF VIRGINIA | |||||||||
| PO BOX 400195 | CHARLOTTESVILLE | VA | 22904 | 546001796 | 501(C)(3) | $118,385 | $0 | RESEARCH | |
| UNIVERSITY OF LOUISIANA AT LAFAYETTE | |||||||||
| 4401 W ADMIRAL DOYLE DRIVE | NEW IBERIA | LA | 70560 | 726023836 | 501(C)(3) | $436,529 | $0 | RESEARCH | |
| DUKE UNIVHUMAN VACCINE INSTITUTE | |||||||||
| 2200 WEST MAIN STREET SUITE 820 | DURHAM | NC | 27705 | 560532129 | 501(C)(3) | $50,641 | $0 | RESEARCH | ERWIN SQUARE PLAZA |
| FRED HUTCHINSON CANCER RESEARCH CTR | |||||||||
| 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109 | 237156071 | 501(C)(3) | $149,634 | $0 | RESEARCH | |
| CATALYSIS FOUNDATION FOR HEALTH IN | |||||||||
| 1900 POWELL STREET SUITE 600 | EMERYVILLE | CA | 94608 | 208602047 | 501(C)(3) | $315,621 | $0 | RESEARCH | |
| UNIVERSITY OF PITTSBURGH | |||||||||
| 200 LOTHROP ST BIOMEDICAL SCIENCE | PITTSBURGH | PA | 15213 | 250965591 | 501(C)(3) | $905,199 | $0 | RESEARCH | TOWER W 950 |
| FRIENDS OF CANCER RESEARCH | |||||||||
| 1800 M STREET NW SUITE 1050 SOUTH | WASHINGTON | DC | 20036 | 521983273 | 501(C)(3) | $138,296 | $0 | RESEARCH | |
| TRANSLATIONAL GENOMICS RESEARCH INSTITUTE | |||||||||
| 446 N FIFTH STREET SUITE 600 | PHOENIX | AZ | 85005 | 331092191 | 501(C)(3) | $86,764 | $0 | RESEARCH | |
| LEIDOS BIOMEDICAL RESEARCH INC | |||||||||
| 1050 BOYLES STREET | FREDERICK | MD | 21702 | 330653185 | CORPORATE ENTITY NOT | $675,756 | $0 | RESEARCH AND DEVELOPMENT | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 28 | Total501c3OrgCnt |
| Total Other Org | 1 | TotalOtherOrgCnt |
Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Type | AWARDS | GrantTypeTxt |
| Recipient | 2 | RecipientCnt |
| Cash Grant | $3,500 | CashGrantAmt |
| Valuation Method Used | FMV | ValuationMethodUsedDesc |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | PROGRAM AND GRANTS MANAGEMENT STAFF INVEST CONSIDERABLE EFFORT IN PROVIDING SCIENTIFIC, ADMINISTRATIVE, AND FISCAL OVERSIGHT FOR FNIH GRANTS. SCIENTIFIC AND TECHNICAL PROGRESS IS MONITORED THROUGH SEMI-ANNUAL AND ANNUAL REPORTS FROM THE GRANTEES AS WELL AS THROUGH DIRECT CONTACT WITH INVESTIGATORS BOTH BY TELECONFERENCE AND SITE VISITS, AND FOLLOW UP TO PROGRESS REPORTS AND SITE VISITS WHERE SCIENTIFIC QUESTIONS OR ADMINISTRATIVE ISSUES ARE IDENTIFIED. SCIENTIFIC REPORT SUBMISSIONS COVER A WIDE RANGE OF ITEMS INCLUDING INDIVIDUAL OBJECTIVES AND OVERALL PROGRESS REVIEW, MILESTONE ACHIEVEMENT, PROJECT PLAN UPDATE, AND ANY OTHER SIGNIFICANT CHANGES. FINANCIAL REPORTING IS REQUIRED ANNUALLY FOR ALL OF THE GRANTEES, AND SEMI-ANNUALLY FOR INSTITUTIONS THAT REQUIRE ADDITIONAL OVERSIGHT, SUCH AS FOR-PROFIT INSTITUTIONS. DUE DILIGENCE PROCEDURES, SUCH AS FNIH COMPLIANCE WITH THE USA PATRIOT ACT AND IRS REQUIREMENTS ON EXPENDITURE RESPONSIBILITIES, HAVE BEEN INCORPORATED INTO THE REPORTING PROCESS TO ENSURE THAT THE GRANTEES ARE COMPLYING WITH GRANT, LEGAL, FINANCIAL, AND REGULATORY REQUIREMENTS. FELLOWS SELECTED FOR FOUNDATION FELLOWSHIPS ARE SELECTED THROUGH NATIONWIDE AND INTERNATIONAL COMPETITIONS. THE CLINICAL RESEARCH TRAINING PROGRAM (CRTP) IS OPEN TO ALL THIRD YEAR STUDENTS ENROLLED IN MEDICAL OR DENTAL SCHOOLS. THE WOMEN'S HEALTH FELLOWSHIP PROGRAMS ARE OPEN TO DOCTORAL-LEVEL CANDIDATES WITHIN FIVE YEARS OF RECEIPT OF THE DOCTORAL DEGREE. APPLICATIONS, CONTAINING TRANSCRIPTS AND ESSAYS ON THEIR RESEARCH GOALS ARE SUBMITTED AND REVIEWED BY PANELS OF NIH SCIENTISTS WHO MAKE RECOMMENDATIONS FOR SELECTION. POTENTIAL FELLOWS ARE OFTEN BROUGHT TO THE CAMPUS FOR INTERVIEWS AND FINAL SELECTION. THE FOUNDATION'S FELLOWSHIPS ARE OPEN TO PROFESSIONALS WORKING AT VARIOUS STAGES OF THEIR RESEARCH CAREERS. APPLICANTS TO THE NEUROSCIENCE FELLOWSHIP, FOR EXAMPLE, ARE YOUNG SCIENTISTS WHO WILL BENEFIT FROM EXPERIENCE OF CLINICAL AND BASIC SCIENCE RESEARCH. THE DIRECTOR'S FELLOWSHIP IN COMPLEMENTARY AND ALTERNATIVE MEDICINE RESEARCH SEEKS A MORE EXPERIENCED SCIENTIST WHO IS WELL-POSITIONED TO BECOME A LEADER IN THE FIELD OF COMPLEMENTARY ALTERNATIVE MEDICINE. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Written Employment Contract | Yes (X) | WrittenEmploymentContractInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | 0 | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (14 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DR MARIA C FREIRE UNTIL SEPT | ||||||||||||||
| PRESIDENT & EXECUTIVE DIRECTOR | $423,587 | $0 | $35,000 | $0 | $0 | $0 | $23,200 | $0 | $0 | $0 | $481,787 | $0 | $0 | $0 |
| DAVID WHOLLEY FROM SEPT | ||||||||||||||
| INTERIM PRES. & EXECUTIVE DIRECTOR | $374,004 | $0 | $35,000 | $0 | $6,300 | $0 | $23,200 | $0 | $15,060 | $0 | $453,564 | $0 | $0 | $0 |
| MICHAEL SANTOS | ||||||||||||||
| VICE PRESIDENT OF SCIENCE | $331,916 | $0 | $10,000 | $0 | $0 | $0 | $23,200 | $0 | $7,180 | $0 | $372,296 | $0 | $0 | $0 |
| STEPHANIE JAMES | ||||||||||||||
| SENIOR SCIENTIFIC ADVISOR | $285,699 | $0 | $0 | $0 | $0 | $0 | $22,463 | $0 | $0 | $0 | $308,162 | $0 | $0 | $0 |
| JOSEPH MENETSKI | ||||||||||||||
| VP, RESEARCH PARTNERSHIPS | $250,098 | $0 | $20,000 | $0 | $0 | $0 | $21,732 | $0 | $12,360 | $0 | $304,190 | $0 | $0 | $0 |
| DONALD HILL | ||||||||||||||
| CHIEF FINANCIAL OFFICER | $254,990 | $0 | $10,000 | $0 | $0 | $0 | $21,532 | $0 | $15,110 | $0 | $301,632 | $0 | $0 | $0 |
| JULIE WOLF-RODDA | ||||||||||||||
| SENIOR VP OF DEVELOPMENT | $240,167 | $0 | $8,000 | $0 | $0 | $0 | $20,133 | $0 | $14,360 | $0 | $282,660 | $0 | $0 | $0 |
| KEVIN A KLOCK | ||||||||||||||
| VP OF OPERATIONS & GENERAL COUNSEL | $226,844 | $0 | $10,000 | $0 | $0 | $0 | $19,412 | $0 | $15,388 | $0 | $271,644 | $0 | $0 | $0 |
| STACEY ADAM | ||||||||||||||
| ASSOCIATE VP, RESEARCH PARTNERSHIPS | $210,835 | $0 | $25,000 | $0 | $0 | $0 | $18,852 | $0 | $7,080 | $0 | $261,767 | $0 | $0 | $0 |
| DAVID O'BROCHTA | ||||||||||||||
| SCIENTIFIC PROGRAM MANAGER | $190,268 | $0 | $5,000 | $0 | $0 | $0 | $15,909 | $0 | $15,110 | $0 | $226,287 | $0 | $0 | $0 |
| KAREN TOUNTAS | ||||||||||||||
| SCIENTIFIC PROGRAM MANAGER | $191,750 | $0 | $2,000 | $0 | $0 | $0 | $15,412 | $0 | $7,080 | $0 | $216,242 | $0 | $0 | $0 |
| STEVEN HOFFMANN | ||||||||||||||
| ASSOCIATE VP, RESEARCH PARTNERSHIPS | $187,977 | $0 | $0 | $0 | $0 | $0 | $15,248 | $0 | $12,360 | $0 | $215,585 | $0 | $0 | $0 |
| BRINDA DASS | ||||||||||||||
| SCIENTIFIC PROGRAM MANAGER | $185,862 | $0 | $3,000 | $0 | $0 | $0 | $15,219 | $0 | $8,830 | $0 | $212,911 | $0 | $0 | $0 |
| ROBERT BALTHASER | ||||||||||||||
| VICE PRESIDENT OF ADVANCEMENT | $171,092 | $0 | $0 | $0 | $0 | $0 | $13,639 | $0 | $7,080 | $0 | $191,811 | $0 | $0 | $0 |
Schedule M IRS990ScheduleM
Cars And Other Vehicles CarsAndOtherVehiclesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 2 | ContributionCnt |
| Noncash Contributions Rpt F990 | $25,092 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | STOCK PRICE | MethodOfDeterminingRevenuesTxt |
Drugs And Medical Supplies DrugsAndMedicalSuppliesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 10 | ContributionCnt |
| Noncash Contributions Rpt F990 | $3,659,164 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | FMV | MethodOfDeterminingRevenuesTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Any Property That Must Be Held | 0 | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | 0 | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | 0 | ThirdPartiesUsedInd |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (9 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART III, LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS CONTINUED: | PARTNERSHIP FOR ACCELERATING CANCER THERAPIES (PACT) IMMUNOTHERAPIES TREATMENTS THAT STIMULATE THE BODY'S OWN IMMUNE SYSTEM TO FIGHT CANCER HAVE PROVEN TO BE AN EFFECTIVE AND PROMISING TREATMENT OPTION FOR CERTAIN CANCERS IN RECENT YEARS. YET THESE IMMUNOTHERAPY TREATMENTS DO NOT WORK FOR ALL PATIENTS, AND WE LACK A PRECISE UNDERSTANDING OF WHY. DEVELOPING STANDARDIZED BIOMARKER TESTS TO UNDERSTAND HOW IMMUNOTHERAPIES WORK IN SOME PATIENTS, AND THUS TO PREDICT PATIENT RESPONSES TO TREATMENT, IS URGENTLY NEEDED FOR THESE THERAPIES TO BENEFIT THE MAXIMUM NUMBER OF PEOPLE. PACT, A FIVE-YEAR PUBLIC-PRIVATE RESEARCH COLLABORATION LAUNCHED IN 2019 BY THE NIH, THE FNIH, THE FDA, AND 12 PHARMACEUTICAL COMPANIES AS PART OF THE CANCER MOONSHOT, INTEGRATES THE EXPERTISE OF RESEARCHERS AT FOUR TOP CANCER RESEARCH CENTERS DANA-FARBER CANCER INSTITUTE, STANFORD UNIVERSITY, MD ANDERSON CANCER CENTER, AND MOUNT SINAI MEDICAL CENTER TO DEVELOP THESE ASSAYS AND HARMONIZE THEM FOR USE ACROSS THE CANCER FIELD. TO DATE, PACT RESEARCHERS HAVE ANALYZED OVER 5,000 SAMPLES FROM 12 CLINICAL TRIALS IN DIFFERENT CANCERS AND USED THE RESULTING DATA TO VALIDATE EXISTING ASSAYS ACROSS ALL FOUR LABORATORIES. SIX EXISTING ASSAYS COMMONLY USED IN ASSESSING IMMUNOTHERAPIES AND COMBINATION THERAPIES ACROSS 15 DIFFERENT CANCERS HAVE BEEN HARMONIZED TO DATE. THE RESULTING STANDARDS HAVE BEEN PUBLISHED IN FOUR MAJOR JOURNAL ARTICLES TO MAKE SURE THESE TESTS CAN BE PERFORMED UNIFORMLY IN LABORATORIES ACROSS THE U.S. AS DATA ANTICIPATED FROM AN ADDITIONAL 35 TRIALS BECOMES AVAILABLE, PACT RESEARCHERS WILL BE ABLE TO USE IT TO HELP DEVELOP NEW BIOMARKERS TO HELP PHYSICIANS SELECT THE MOST OPTIMAL IMMUNOTHERAPY TREATMENTS FOR THEIR PATIENTS. MUCOSAL HEALING FOR ULCERATIVE COLITIS IN APRIL 2021, THE FNIH BIOMARKERS CONSORTIUM LAUNCHED ITS MUCOSAL HEALING IN ULCERATIVE COLITIS (UC) PROJECT TO IMPROVE DIAGNOSIS AND TREATMENT OF A DEBILITATING INFLAMMATORY BOWEL DISEASE THAT AFFECTS MORE THAN THREE MILLION PEOPLE WORLDWIDE. THIS THREE-YEAR INITIATIVE AIMS TO GENERATE BEST PRACTICES AND CONSENSUS STANDARDS FOR ASSESSING DISEASE ACTIVITY AT THE TISSUE-LEVEL IN UC CLINICAL TRIALS. THE PROGRAM ALSO HOPES TO DEVELOP CUTTING-EDGE METHODOLOGIES TO MEASURE MUCOSAL HEALING THE BODY'S ABILITY TO RESTORE INTESTINAL LINING DAMAGED BY UC, AND AN IMPORTANT OUTCOME IN CLINICAL TRIALS MORE ACCURATELY IN THE FUTURE. CREATING A MORE PRECISE MEASURE WITH WHICH TO JUDGE THE OUTCOME OF CLINICAL TRIALS PROMISES TO MEANINGFULLY ACCELERATE THE DEVELOPMENT OF NEW THERAPIES FOR PATIENTS WITH UC. THE ABILITY TO USE A COMMON PROTOCOL AND AUTOMATE THE EVALUATION OF MUCOSAL INFLAMMATION AND HEALING WILL ENABLE THESE MEASUREMENTS TO BE APPLIED MORE CONSISTENTLY, PRECISELY, AND RAPIDLY AND MAY REDUCE THE NUMBER OF BIOPSIES NEEDED. THE GOAL IS TO ADVANCE PHYSICIANS' ABILITY TO HELP GUIDE APPROPRIATE TREATMENT TO REDUCE OR EVEN PREVENT RELAPSES AND COMPLICATIONS, IMPROVING THE PATIENT EXPERIENCE. GENECONVENE IN THE MIDST OF AN ALREADY-STALLED GLOBAL STRUGGLE AGAINST MALARIA, COVID-19-RELATED DISRUPTIONS TO HEALTH CARE SYSTEMS PROMPTED A DANGEROUS RESURGENCE OF THIS DEADLY DISEASE IN 2020. RECOGNIZING THE URGENT NEED FOR NEW STRATEGIES, IN MAY 2021 THE WORLD HEALTH ORGANIZATION (WHO) WITH SUPPORT FROM FNIH'S GENECONVENE GLOBAL COLLABORATIVE PUBLISHED AN UPDATED GUIDANCE FRAMEWORK TO INFORM RESEARCH AND DEVELOPMENT OF GENETICALLY MODIFIED MOSQUITOES. MODIFYING THE GENES OF MALARIA-CARRYING MOSQUITOES CAN REDUCE THEIR ABILITY TO REPRODUCE, SO THAT THERE ARE FEWER TO SPREAD THE DISEASE, AND MAY DECREASE THE MOSQUITOES' ABILITY TO TRANSMIT THE MALARIA PARASITE. IF PROVEN SAFE, EFFECTIVE, AND AFFORDABLE, THESE TECHNOLOGIES COULD OFFER A GAME-CHANGING ADDITION TO THE EXISTING ARSENAL OF INTERVENTIONS AGAINST MALARIA. BUT THERE ARE MANY IMPORTANT QUESTIONS FOR DECISION MAKERS TO ADDRESS WHEN EVALUATING WHETHER AND HOW TO MOVE FORWARD WITH RESEARCH AND IMPLEMENTATION. THE FNIH-LED GENECONVENE INITIATIVE WORKS TO ENSURE THAT ALL STAKEHOLDERS INCLUDING RESEARCHERS, POLICYMAKERS, REGULATORS, AND COMMUNITIES AFFECTED BY MALARIA ARE EQUIPPED WITH THE RIGHT TOOLS TO MAKE INFORMED, RESPONSIBLE DECISIONS ABOUT THESE TECHNOLOGIES. THE NEW WHO GUIDANCE IS A SIGNIFICANT MILESTONE IN THIS EFFORT. IT PROVIDES ANSWERS TO SOME OF THE TOUGHEST QUESTIONS IN THE FIELD, INCLUDING: - HOW CAN THE POTENTIAL EFFECTIVENESS AND RISKS OF GENETICALLY MODIFIED MOSQUITOES ON REDUCING DISEASE BE EVALUATED? - WHAT ARE THE KEY ETHICAL CONSIDERATIONS? - WHICH REGULATORY FRAMEWORKS WILL OVERSEE DECISIONS ABOUT RESEARCH? LIKE MANY OTHER FNIH COLLABORATIONS, GENECONVENE CENTERS ON A CRITICAL INFLECTION POINT WHERE ADVANCES IN BIOMEDICAL RESEARCH DEPEND ON BRINGING DIVERSE GROUPS TOGETHER TO PURSUE A COMMON GOAL. WITH MALARIA CAUSING MORE THAN 600,000 DEATHS WORLDWIDE IN 2020 ALONE, THERE IS AN URGENT NEED TO EVALUATE THE PROMISE OF GENETICALLY MODIFIED MOSQUITOES BOTH QUICKLY AND RESPONSIBLY. GENECONVENE ALSO SERVES AS A GLOBAL HUB FOR RELEVANT, TIMELY AND ACCURATE KNOWLEDGE. A KEY RESOURCE FOR THIS WORK IS THE GENECONVENE VIRTUAL INSTITUTE, ALSO LAUNCHED IN 2020. THE VIRTUAL INSTITUTE IS AN ONLINE LIBRARY HOUSING SCHOLARLY LITERATURE, POLICY PAPERS, OPINION PIECES, EDUCATIONAL VIDEOS AND MEDIA COVERAGE. GENECONVENE ALSO HOSTS REGULAR WEBINARS THAT PROVIDE DIVERSE, MULTIDISCIPLINARY PERSPECTIVES ON THE SCIENTIFIC, SOCIAL AND ETHICAL DIMENSIONS OF GENETIC BIOCONTROL TECHNOLOGIES. REALIZING THE IMMENSE PROMISE OF GENETIC BIOCONTROL RESEARCH TO END MALARIA AND OTHER MOSQUITO-BORNE DISEASES OVER THE LONG TERM WILL REQUIRE A RIGOROUS EVALUATION OF THE RISKS AND BENEFITS OF EACH STEP ALONG THE WAY, FROM THE LABORATORY TO FIELD TESTING TO POTENTIAL IMPLEMENTATION. THROUGH THE GENECONVENE GLOBAL COLLABORATIVE, FNIH IS COMMITTED TO ENSURING THAT EVERYONE CHARGED WITH MAKING DECISIONS ABOUT GENETIC BIOCONTROLFROM SCIENTISTS TO POLICYMAKERS TO COMMUNITIESHAS THE KNOWLEDGE THEY NEED TO MOVE FORWARD SAFELY AND ETHICALLY. GENE DRIVE RESEARCH FORUM HUNDREDS OF PARTICIPANTS AROUND THE WORLD JOINED A 2021 SERIES OF VIRTUAL DISCUSSIONS COHOSTED BY GENECONVENE AND MCMASTER UNIVERSITY IN ONTARIO, CANADA, TO EXPLORE CRITICAL ETHICAL QUESTIONS RELATED TO GENE DRIVE. TOPICS INCLUDED THE ETHICAL PRINCIPLES THAT SHOULD GOVERN GENE DRIVE RESEARCH, AND JUSTICE AND EQUITY CONSIDERATIONS FOR APPLYING GENE DRIVE AT THE LOCAL COMMUNITY LEVEL. THE GENE DRIVE RESEARCH FORUM ORGANIZED BY GENECONVENE DEVELOPED THESE PANELS, AS WELL AS A COMPANION SERIES COHOSTED BY GENECONVENE AND THE GENETIC BIOCONTROL OF INVASIVE RODENTS (GBIRD) PARTNERSHIP THAT FOCUSED ON BEST PRACTICES FOR ENGAGING STAKEHOLDERS TO EXPLORE GENE DRIVE TECHNOLOGIES TOGETHER. COMPREHENSIVE CELLULAR VACCINE IMMUNE MONITORING CONSORTIUM (CCVIMC) IN JULY 2021, THE GATES FOUNDATION RENEWED FOR ANOTHER FIVE YEARS THE REMARKABLE WORK OF THE FNIH COMPREHENSIVE CELLULAR VACCINE IMMUNE MONITORING CONSORTIUM (CCVIMC). FOCUSED ON SUPPORTING THE DEVELOPMENT OF AN EFFECTIVE VACCINE FOR THE HIV VIRUS THAT CAUSES AIDS, THE CCVIMC CONVENES LEADING SCIENTISTS ACROSS THE GLOBE TO PROVIDE STANDARDIZED MEASUREMENTS FROM CLINICAL AND PRE-CLINICAL STUDIES OF THE DISEASE AND SHARE DATA TO OPTIMIZE VACCINE PLATFORMS BEING DEVELOPED THROUGH THE COLLABORATION FOR AIDS VACCINE DISCOVERY. GLOBALLY 1.5 MILLION PEOPLE ARE INFECTED WITH HIV ANNUALLY. OVER THE NEXT FIVE YEARS THE CCVIMC WILL CONTINUE TO BUILD ON RESEARCH ENABLING NEW APPROACHES TO HIV VACCINES TO BE STUDIED. THE END GOAL IS DEVELOPMENT OF A SAFE AND BROADLY EFFECTIVE VACCINE THAT WILL PREVENT HIV INFECTION. |
| FORM 990, PART VI, SECTION A, LINE 1A | THE BOARD HAS AN EXECUTIVE COMMITTEE, WHICH CAN MAKE DECISIONS ON BEHALF OF THE BOARD (WITH SOME EXCEPTIONS) IN BETWEEN BOARD MEETINGS. |
| FORM 990, PART VI, SECTION A, LINE 2 | MARIA FREIRE, THE FNIH PRESIDENT AND EXECUTIVE DIRECTOR UNTIL SEPTEMBER 2021, IS A NON-EXECUTIVE MEMBER OF THE BOARD OF DIRECTORS OF ALEXANDRIA REAL ESTATE. JOEL MARCUS IS THE CHAIRMAN AND CEO OF ALEXANDRIA REAL ESTATE AND A NON-EXECUTIVE MEMBER OF THE FNIH BOARD OF DIRECTORS. |
| FORM 990, PART VI, SECTION A, LINE 4 | THE FNIH BY-LAWS WERE AMENDED IN MAY 2021 TO MAKE CHANGES TO THE TERMS OF MEMBERS OF THE BOARD OF DIRECTORS. |
| FORM 990, PART VI, SECTION B, LINE 11B | PRIOR TO THE SUBMISSION OF THE FOUNDATION FOR NIH'S FORM 990 TO THE INTERNAL REVENUE SERVICE, EACH VOTING MEMBER OF THE BOARD OF DIRECTORS SHALL BE PROVIDED WITH A COPY OF THE DRAFT FORM 990 AS APPROVED BY THE CHIEF FINANCIAL OFFICER. |
| FORM 990, PART VI, SECTION B, LINE 12C | DIRECTORS, OFFICERS AND EMPLOYEES ARE REQUIRED TO ANNUALLY SIGN A STATEMENT WHICH AFFIRMS THAT THEY HAVE: O RECEIVED A COPY OF THE CONFLICT OF INTEREST POLICY O READ, UNDERSTOOD AND AGREED TO COMPLY WITH THE POLICY O RECEIVED AND REVIEWED A LISTING OF CORPORATE AND FOUNDATION DONORS, CONTRACTORS, VENDORS, GRANTEES, PRINCIPAL INVESTIGATORS AND FINANCIAL INSTITUTIONS WITH WHOM THE FNIH HAS A CURRENT RELATIONSHIP O NO ACTUAL OR APPARENT CONFLICTS OF INTEREST OTHER THAN THOSE DISCLOSED IN THE STATEMENT. THEY MUST ALSO MAKE CERTAIN NOTIFICATIONS IN PARTICULAR CIRCUMSTANCES. THE CONFLICT OF INTEREST POLICY ALSO HAS MECHANISMS FOR HANDLING SUCH CONFLICTS. |
| FORM 990, PART VI, SECTION B, LINE 15 | THE COMPENSATION COMMITTEE OF THE BOARD REVIEWED AND CONCURRED WITH THE PRESIDENT AND EXECUTIVE DIRECTOR'S DECISIONS ESTABLISHING AND ADJUSTING THE SENIOR EXECUTIVE TEAM'S ANNUAL SALARIES AND RELATED COMPENSATION DECISIONS. THE COMPENSATION COMMITTEE ALSO APPROVED THE COMPENSATION LEVEL OF THE PRESIDENT AND EXECUTIVE DIRECTOR AND RELATED COMPENSATION DECISIONS. |
| FORM 990, PART VI, SECTION C, LINE 19 | ALL SUCH DOCUMENTS ARE AVAILABLE UPON REQUEST. IN ADDITION, THE GOVERNING DOCUMENTS AND FINANCIAL STATEMENTS ARE AVAILABLE ON THE FNIH WEBSITE. |
| FORM 990, PART XII, LINE 2C: | PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR. |